Listen on the go
Downloads

View and download resources from this activity to support your learning

Download Article
CORRECT!
Next question
Faculty & Disclosures
Dr Benjamin Weinberg, MD

Associate Professor of Medicine and attending physician

Dr Benjamin Weinberg, MD is an Associate Professor of Medicine and attending physician. He specializes in gastrointestinal oncology and sarcoma. His research includes the development of new therapies for colorectal and pancreatic cancers, which includes the molecular characterization of mutations and actionable targets.

Disclosures: speaker’s fees from Merus  

Dr Joeffrey Chahine, PhD

Technical Director Molecular Diagnostics Laboratory

Disclosures: speaker’s fees from Merus

touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Pancreatic Cancer

    An Introduction to Pancreatic Cancer

    Pancreatic cancer is one of the most devastating malignancies worldwide, with a 5-year overall survival of less than 8%. Surgical resection followed by adjuvant chemotherapy is currently the only curative therapy available, but only 10-20% of patients present with resectable disease. At present, combined approaches involving radiotherapy in conjunction with targeted therapies or immunotherapies offer the best outcomes. However, advances in sequencing technologies have enabled a detailed analysis of genetic alterations, mutational burden, expression pattern, and stroma composition and identified disease subtypes, which will hopefully translate into novel therapeutic approaches.

    Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Pancreatic Cancer Content

    touchFEATURE
    The role of RNA-based next-generation sequencing in identifying pathogenic gene fusions
    For HCPs in: USA
    View Time: 15 mins Sponsored content

    A review of next-generation sequencing methods for identifying actionable gene fusions and improving outcomes in cancer patients.

     

    MAT-0085
    Date of Preparation: December 2023
    Gastrointestinal Cancers, Pancreatic Cancer
    Developed by Touch
    Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
    Watch Time: 8 mins

    Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]

    Gastrointestinal Cancers, Pancreatic Cancer
    Developed by Touch
    Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
    Watch Time: 1 min

    Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]

    touchFEATURE
    NETTER-1: a Phase 3 clinical trial in patients with midgut neuroendocrine tumours (NET)
    For HCPs in: Europe
    View Time: 20 mins Sponsored content

    Discover key results from an international, randomised, active-control study in patients with inoperable, progressive midgut NET.1

    Prescribing Infomation

    AAA-Lu177-GL-0380
    Date of Preparation: September 2022
    Pancreatic Cancer
    Marcus S Noel
    Developed by Touch
    Marcus S Noel, ASCO GI22: Latest Advances in Pancreatic Cancer Treatment
    Watch Time: 4 mins

    touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions       What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00       Could […]

    Pancreatic Cancer
    Developed by Touch
    Benjamin A Weinberg, ASCO GI22: Pivotal Studies in Pancreatic Cancer
    Watch Time: 8 mins

    touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022. Questions What are the hopes of the new drug delivery mechanism using L-asparaginase to treat […]

    Pancreatic Cancer
    Improving Outcomes in Pancreatic Cancer
    Reya Sharman, Rachna T Shroff

    Oncology & Haematology Review (US). 2020;16(1):59–66 DOI: https://doi.org/10.17925/OHR.2020.16.1.59

    Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In this review, we will summarize the molecular characteristics and mutations thought to be involved with […]

    Pancreatic Cancer
    The APACT study – efficacy of nab-paclitaxel/gemcitabine compared with gemcitabine in patients with surgically resected pancreatic cancer

    Over the past two decades, gemcitabine has been the first-choice adjuvant therapy for advanced pancreatic cancer.1 Recent trial findings have evolved first-line standard of care; longer survival times and higher response rates have been achieved with combination treatments, compared with gemcitabine alone.1–3 The MPACT trial demonstrated survival benefits with nab-paclitaxol plus gemcitabine over gemcitabine alone […]

    Pancreatic Cancer
    Michel Ducreux, ESMO 2019 – Treating advanced pancreatic cancer

    We joined Michel Ducreux at ESMO 2019 to discuss the challenges and recent advances in treating pancreatic cancer. Questions 1. What are the major challenges in the treatment of advanced pancreatic cancer? (00:04) 2. Why is it important to treat advanced pancreatic cancer faster? (00:30) 3. What have been the most important recent clinical advances […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup